Medulloblastoma epitomizes the war against childhood cancer. Although this small round blue-cell tumor accounts for only 20% of all childhood brain tumors, or just fewer than 600 new cases each year in the United States, medulloblastoma has nevertheless become a paradigm for biologic study, clinical investigation, and assessment of late effects. Craniospinal irradiation historically became the mainstay of therapy for this WHO grade 4 neoplasm because of its propensity to disseminate throughout the neuraxis via the subarachnoid space. By the 1970s, 36 Gy of craniospinal radiotherapy resulted in 5-year survival of greater than 50% for better-risk patients. With cooperative group trials in the 1980s, adjuvant chemotherapy was introduced to medulloblastoma treatment protocols (SIOP I [International Society of Paediatric Oncology], CCG 942 [Children’s Cancer Group], and POG 7909 [Pediatric Oncology Group]), leading to improved survival and subsequent reduction of radiotherapy dosage for averagerisk patients in the 1990s and early part of the last decade. A decrease in craniospinal radiotherapy from 36 Gy to 23.4 Gy resulted in better neurocognitive and physical outcomes for average-risk patients, highlighting the importance of developing appropriately riskadapted therapy. Although prognosis has improved over many years, a significant fraction of children still do not respond to standard therapy. Perhaps equally disturbing, survivors are left with a multitude of sequelae attributable to chemotherapy and radiation therapy, including cognitive impairment, hearing loss, neuropathies, seizures, endocrinopathies, strokes, and second malignancies. Thus, there is an overwhelming need to refine strategies that will minimize unnecessarily aggressive therapy for patients with low-risk disease and maximize efficacious treatment for patients with high-risk disease. Such refinement can come only with better disease or risk classification. In an era of genomic profiling, risk stratification for medulloblastoma disappointingly remains strictly clinical, based solely on age, resection extent, Chang metastasis staging, and more recently anaplasia. Since the mid 1990s, a two-tiered risk stratification system has been employed for the purposes of North American cooperative group trials. Patients older than 3 years with less than 1.5 cm of residual tumor and nonmetastatic disease are considered average risk, whereas those younger than 3 years with more than 1.5 cm of residual tumor, evidence of tumor dissemination, or diffuse anaplasia are considered high risk. Multiple histopathologic, cytogenetic, and molecular factors have been found to influence prognosis, but to date, none have been incorporated into the risk-stratification system. Histopathologically, the desmoplastic variant has long been recognized as connoting better prognosis, whereas the large-cell anaplastic variant more recently has been found to be associated with reduced survival. Moreover, isochromosome 17q, loss of heterozygosity at chromosome 17p, and high-level chromosomal gain at 8q24 (locus of c-MYC) have all been associated with large-cell anaplastic variant medulloblastoma and poor prognosis. Monosomy 6 has been associated with favorable prognosis. In addition, a number of molecular markers have been identified over the past decade and have laid the groundwork for a risk-stratification system with a biologic basis. Favorable prognosis has been described for children with high TrkC expression or nucleopositivity of -catenin, an indicator of activated Wnt signaling—a pathway now known to affect embryogenesis and cancer. Poor prognosis is indicated by overexpression of calbindin-D, elevated ErbB2 expression, and elevated expression of c-MYC, a member of the MYC family of transcription factors that stimulates cell proliferation. In recent years, large-scale genomic and gene expression profile studies have begun to parse the molecular heterogeneity of medulloblastomas into clear subtypes with associated risk stratification. Initial gene expression microarray studies used a supervised approach, grouping samples on the basis of histology, metastatic status, and survival to identify differentially expressed genes in these clinical and histologic groups. More recently, unsupervised microarray studies in medulloblastoma by Kool et al (62 samples) and Thompson et al (46 samples) each identified up to five subgroups of medulloblastoma, including a subgroup characterized by activation of the Wnt signaling pathway, associated with excellent prognosis, and a subgroup characterized by activation of the Hedgehog (Hh) signaling pathway occurring primarily in infants and adults and associated with desmoplastic histology. The Hh signaling pathway is involved in organogenesis, limb formation, brain patterning, and multiple forms of cancer. There are several Hh family ligands, the best known of which is Sonic Hedgehog (SHh) for its multiple developmental roles, including in cerebellar development. The study by Kool et al also identified a molecular subtype associated with a high rate of metastatic disease, anaplastic/ large-cell histology, and poor prognosis. In this issue of Journal of Clinical Oncology, four separate studies dovetail with previous work to crystallize a molecular classification of medulloblastoma and codify a new risk-stratification model on the basis of the molecular biology of these disease subtypes. Ellison et al JOURNAL OF CLINICAL ONCOLOGY E D I T O R I A L S VOLUME 29 NUMBER 11 APRIL 1
Read full abstract
May 5, 2015
Qin Li + 9
Open Access
